DIURIL INJ Rx
Generic Name and Formulations:
Chlorothiazide (as sodium) 500mg/vial; pwd for IV inj after reconstitution; contains mannitol.
Indications for DIURIL INJ:
0.5–1g IV once or twice daily.
Anuria. Sulfonamide allergy.
Renal or hepatic impairment. Arrhythmias. Diabetes. Gout. Asthma. SLE. Postsympathectomy. Excessive fluid loss. Monitor electrolytes, BUN (if high). Potassium supplements or K+ -sparing diuretics may be needed. Discontinue if electrolyte disorders develop rapidly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Digitalis, lithium toxicity. Adjust antidiabetic, antigout medications. Antagonized by NSAIDs. ACTH, corticosteroids, amphotericin B increase hypokalemia risk. Hyperglycemia, hyperuricemia more likely with diazoxide. NSAIDs may cause renal failure. May potentiate nondepolarizing muscle relaxants, other antihypertensives. Hypotension with CNS depressants. May interfere with parathyroid tests.
Electrolyte disorders (especially hypokalemia), hyperglycemia, hyperuricemia, photosensitivity, orthostatic hypotension, GI disturbances, adverse lipid values.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|